In 2018, Chinese scientist He Jiankui stunned the world by announcing the creation of the first gene-edited babies, a groundbreaking move that quickly spiraled into one of the most controversial scientific scandals of the century. This initiative aimed to shield the newborns from HIV but led to global outcry and immense ethical debates. The repercussions included He’s imprisonment and a strict ban on genome editing for reproductive purposes in China.
After serving a three-year sentence, He re-emerges with ambitious new plans, having seemingly learned little from the prior ethical discussions clouding his previous work. Initially pivoting towards gene therapy targeting Duchenne muscular dystrophy, He’s current attention is fixed on Alzheimer’s prevention. He is exploring the APP-A673T mutation, a naturally occurring genetic variant found in some Icelandic populations, known for conferring resistance to Alzheimer’s disease and even enhancing longevity.
His intention is to introduce this mutation into human germlines, essentially rewriting genetic codes that future generations will inherit. While such a concept teeters on the edge of medical marvel and ethical trespass, He Jiankui remains undeterred. He is actively seeking financial backers and conducting preparatory research involving mice and monkey embryos. Though still in preclinical stages, the ultimate goal includes human trials, potentially in countries with more permissive legislation regarding genetic modifications, such as South Africa.
He Jiankui positions his work as distinctly medical, contrasting it with tech-driven initiatives that aim to create so-called “designer babies.” He firmly opposes genetic enhancements like altering intelligence or physical traits, which he argues stray into the problematic realm of eugenics. Instead, he envisions an approach focused exclusively on disease prevention.
Key Takeaways:
-
Shifting Targets: He Jiankui redirects his focus from HIV prevention to combating Alzheimer’s through gene-editing technologies, post-imprisonment.
-
Leveraging Natural Mutations: He plans to utilize the APP-A673T mutation, prized for its Alzheimer’s resistance, raising hopes and ethical eyebrows alike.
-
Legal and Ethical Maze: Despite strict regulations and a turbulent past, He presses on, courting private investments and considering international locations for future trials.
-
Distinct Positioning: He draws a clear line between medical prevention of genetic diseases and the ethical pitfalls of creating “designer” genes or traits.
The global scientific community watches He’s journey with a mix of skepticism and anticipation, cautiously evaluating the potential health breakthroughs against the deeply rooted ethical challenges of altering human germlines. As genetic technology advances, society grapples with the moral implications of its applications, asking whether the potential benefits justify the ethical leaps required.